Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 174 articles:
HTML format



Single Articles


    January 2021
  1. HEFFERNAN A, Ma Y, Nayagam S, Chan P, et al
    Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China.
    PLoS One. 2021;16:e0245288.
    PubMed     Abstract available


  2. HUANG YC, Huang CF, Liu SF, Liu HY, et al
    The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
    PLoS One. 2021;16:e0246376.
    PubMed     Abstract available


  3. LIN CP, Liang PC, Huang CI, Yeh ML, et al
    Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2021;16:e0245479.
    PubMed     Abstract available


  4. BAKER JD, Uhrich RL, Kraemer GC, Love JE, et al
    A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
    PLoS One. 2021;16:e0245962.
    PubMed     Abstract available


  5. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2021;16:e0245767.
    PubMed     Abstract available


  6. KWON JA, Chambers GM, Luciani F, Zhang L, et al
    Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
    PLoS One. 2021;16:e0245896.
    PubMed     Abstract available


  7. MAJD JABBARI S, Maajani K, Merat S, Poustchi H, et al
    An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
    PLoS One. 2021;16:e0246594.
    PubMed     Abstract available


  8. ANWAR WA, El Gaafary M, Girgis SA, Rafik M, et al
    Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt.
    PLoS One. 2021;16:e0246836.
    PubMed     Abstract available


  9. GRUBYTE S, Urboniene J, Nedzinskiene L, Jelinskaite A, et al
    Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.
    PLoS One. 2021;16:e0246704.
    PubMed     Abstract available


  10. MUHLBACHER AC, Sadler A
    Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
    PLoS One. 2021;16:e0245480.
    PubMed    


  11. METWALLY AM, Elmosalami DM, Elhariri H, El Etreby LA, et al
    Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study.
    PLoS One. 2021;16:e0242257.
    PubMed     Abstract available


  12. HO H, Janjua NZ, McGrail KM, Harrison M, et al
    The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
    PLoS One. 2021;16:e0247843.
    PubMed     Abstract available


  13. RAJHI M, Haddad-Boubaker S, Chouikha A, Bourquain D, et al
    Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w).
    PLoS One. 2021;16:e0248249.
    PubMed     Abstract available


  14. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
    A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
    PLoS One. 2021;16:e0247277.
    PubMed     Abstract available


  15. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
    Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PLoS One. 2021;16:e0248748.
    PubMed     Abstract available


  16. HERNANDEZ CJ, Trujillo D, Sicro S, Meza J, et al
    High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.
    PLoS One. 2021;16:e0249219.
    PubMed     Abstract available


  17. TONEN-WOLYEC S, Djang'eing'a RM, Batina-Agasa S, Kayembe Tshilumba C, et al
    Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.
    PLoS One. 2021;16:e0249701.
    PubMed     Abstract available


  18. MIRZAZADEH A, Chen YH, Lin J, Burk K, et al
    Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
    PLoS One. 2021;16:e0249585.
    PubMed     Abstract available


  19. AHMED HR, Waly NGFM, Abd El-Baky RM, Yahia R, et al
    Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    PLoS One. 2021;16:e0249770.
    PubMed     Abstract available


  20. PONNUVEL S, Fletcher GJ, Anantharam R, Varughese S, et al
    Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
    PLoS One. 2021;16:e0250263.
    PubMed     Abstract available


  21. PALAYEW A, Schmidt AM, Saeed S, Cooper CL, et al
    Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada.
    PLoS One. 2021;16:e0249836.
    PubMed     Abstract available


  22. KAARTINEN K, Vuoti S, Honkanen E, Loyttyniemi E, et al
    Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.
    PLoS One. 2021;16:e0251392.
    PubMed     Abstract available


  23. LEE CY, Wu PH, Lu MW, Chen TC, et al
    High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.
    PLoS One. 2021;16:e0251158.
    PubMed     Abstract available


  24. BUGGISCH P, Heiken H, Mauss S, Weber B, et al
    Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
    PLoS One. 2021;16:e0250833.
    PubMed     Abstract available


  25. IREKEOLA AA, Malek NA, Wada Y, Mustaffa N, et al
    Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251673.
    PubMed     Abstract available


  26. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    PubMed     Abstract available


  27. DIDIYA R, Gyenwali D, Pokhrel TN, Devkota S, et al
    Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
    PLoS One. 2021;16:e0252490.
    PubMed     Abstract available


  28. WURCEL AG, Reyes J, Zubiago J, Koutoujian PJ, et al
    "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
    PLoS One. 2021;16:e0250901.
    PubMed     Abstract available


  29. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    PubMed     Abstract available


  30. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    PubMed     Abstract available


  31. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    PubMed     Abstract available


  32. GAHRTON C, Hakansson A, Kaberg M, Jerkeman A, et al
    Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
    PLoS One. 2021;16:e0253710.
    PubMed     Abstract available


  33. TORO DM, Ramasawmy R, Silva Neto PV, Pereira GL, et al
    Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil.
    PLoS One. 2021;16:e0253470.
    PubMed     Abstract available


  34. RAHMAN S, Wathington D, Waterboer T, Pawlita M, et al
    Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.
    PLoS One. 2021;16:e0253005.
    PubMed     Abstract available


  35. LIU HY, Lin YH, Lin PJ, Tsai PC, et al
    Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
    PLoS One. 2021;16:e0254028.
    PubMed     Abstract available


  36. LLORENS-REVULL M, Costafreda MI, Rico A, Guerrero-Murillo M, et al
    Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    PLoS One. 2021;16:e0254243.
    PubMed     Abstract available


  37. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    PubMed     Abstract available


  38. PRENTOE J, Janitzek CM, Velazquez-Moctezuma R, Goksoyr L, et al
    Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
    PLoS One. 2021;16:e0255336.
    PubMed     Abstract available


  39. DEFANTE FERRETO LE, Guedes S, Braz Pauli F, Soligo Rovani S, et al
    Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0255173.
    PubMed     Abstract available


  40. SINN DH, Kang D, Hong YS, Koh KC, et al
    Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
    PLoS One. 2021;16:e0255624.
    PubMed     Abstract available


  41. YUNIHASTUTI E, Hariyanto R, Sulaiman AS, Harimurti K, et al
    Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia.
    PLoS One. 2021;16:e0256164.
    PubMed     Abstract available


  42. AHSAN A, Dar S, Hassan F, Ghafoor F, et al
    Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    PLoS One. 2021;16:e0256816.
    PubMed     Abstract available


  43. KOBAYASHI H, Joshita S, Akahane Y, Matsuzaki K, et al
    Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project.
    PLoS One. 2021;16:e0256711.
    PubMed     Abstract available


  44. CHEN YC, Li CH, Ko PH, Lee CC, et al
    Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
    PLoS One. 2021;16:e0256505.
    PubMed     Abstract available


  45. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
    A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
    PLoS One. 2021;16:e0257166.
    PubMed     Abstract available


  46. KWON JA, Dore GJ, Hajarizadeh B, Alavi M, et al
    Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    PLoS One. 2021;16:e0257369.
    PubMed     Abstract available


  47. MIZUNO K, Haga H, Okumoto K, Hoshikawa K, et al
    Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver.
    PLoS One. 2021;16:e0249556.
    PubMed     Abstract available


  48. KONG L, Karns R, Shata MTM, Brown JL, et al
    The synthetic opioid fentanyl enhances viral replication in vitro.
    PLoS One. 2021;16:e0249581.
    PubMed     Abstract available


  49. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
    Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
    PLoS One. 2021;16:e0249435.
    PubMed     Abstract available


  50. LEE SO, Lee JE, Lee S, Lee SH, et al
    Prevalence and patterns of illicit drug use in people with human immunodeficiency virus infection in Korea.
    PLoS One. 2021;16:e0249361.
    PubMed     Abstract available


  51. MAZHAR MKA, Finger F, Evers ES, Kuehne A, et al
    An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox's Bazar, Bangladesh: Findings from enhanced epidemiological surveillance.
    PLoS One. 2021;16:e0250505.
    PubMed     Abstract available


  52. AFANEH H, Straif-Bourgeois S, Oral E, Wennerstrom A, et al
    Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol.
    PLoS One. 2021;16:e0257437.
    PubMed     Abstract available


  53. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
    The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection.
    PLoS One. 2021;16:e0258143.
    PubMed     Abstract available


  54. ELKARANSHAWY HA, Ezzat HM, Ibrahim NN
    Lyapunov function and global asymptotic stability for a new multiscale viral dynamics model incorporating the immune system response: Implemented upon HCV.
    PLoS One. 2021;16:e0257975.
    PubMed     Abstract available


  55. MREMI A, Yahaya JJ, Nyindo M, Mollel E, et al
    Transfusion-Transmitted Infections and associated risk factors at the Northern Zone Blood Transfusion Center in Tanzania: A study of blood donors between 2017 and 2019.
    PLoS One. 2021;16:e0249061.
    PubMed     Abstract available


  56. KLOK S, van Dulm E, Boyd A, Generaal E, et al
    Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections among undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019.
    PLoS One. 2021;16:e0258932.
    PubMed     Abstract available


  57. ADANE T, Getawa S
    The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251570.
    PubMed     Abstract available


  58. FERRETO LED, Guedes SJKO, Pauli FB, Rovani SS, et al
    Correction: Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0260179.
    PubMed     Abstract available


  59. ISRAR M, Ali F, Nawaz A, Idrees M, et al
    Seroepidemiology and associated risk factors of hepatitis B and C virus infections among pregnant women attending maternity wards at two hospitals in Swabi, Khyber Pakhtunkhwa, Pakistan.
    PLoS One. 2021;16:e0255189.
    PubMed     Abstract available


    January 2020
  60. RIVERO-JUAREZ A, Guijo-Rubio D, Tellez F, Palacios R, et al
    Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals.
    PLoS One. 2020;15:e0227188.
    PubMed     Abstract available


  61. TSAI WL, Wang CF, Cheng JS, Chen WC, et al
    Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience.
    PLoS One. 2020;15:e0227424.
    PubMed     Abstract available


  62. SHAO LN, Zhang ST, Wang N, Yu WJ, et al
    Platelet indices significantly correlate with liver fibrosis in HCV-infected patients.
    PLoS One. 2020;15:e0227544.
    PubMed     Abstract available


  63. GOOD SS, Moussa A, Zhou XJ, Pietropaolo K, et al
    Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.
    PLoS One. 2020;15:e0227104.
    PubMed     Abstract available


  64. NUTINI MFR, Hunter J, Giron L, Pires AFNPC, et al
    HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country.
    PLoS One. 2020;15:e0227082.
    PubMed     Abstract available


  65. LIU GY, Tang O, Brotman DJ, Miller ER 3rd, et al
    Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy.
    PLoS One. 2020;15:e0224977.
    PubMed     Abstract available


  66. HUHN GD, Ramgopal M, Jain MK, Hinestrosa F, et al
    HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PLoS One. 2020;15:e0224875.
    PubMed     Abstract available


  67. SAINE ME, Moore TM, Szymczak JE, Bamford LP, et al
    Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection.
    PLoS One. 2020;15:e0228471.
    PubMed     Abstract available


  68. PATEL SV, Jayaweera DT, Althoff KN, Eron JJ, et al
    Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
    PLoS One. 2020;15:e0228847.
    PubMed     Abstract available


  69. LEE KS, Quintiliani L, Heinz A, Johnson NL, et al
    A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
    PLoS One. 2020;15:e0228767.
    PubMed     Abstract available


  70. CARVALHO-GOMES A, Cubells A, Pallares C, Hontangas V, et al
    A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.
    PLoS One. 2020;15:e0228351.
    PubMed     Abstract available


  71. SIRINAWASATIEN A, Techasirioangkun T
    Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PLoS One. 2020;15:e0229517.
    PubMed     Abstract available


  72. CASTRO R, Perazzo H, de Araujo LAMM, Gutierres IG, et al
    Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis.
    PLoS One. 2020;15:e0229143.
    PubMed     Abstract available


  73. LIN SF, Tung SY, Wei KL, Chen CH, et al
    Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
    PLoS One. 2020;15:e0229994.
    PubMed     Abstract available


  74. SCHMIDBAUER C, Schubert R, Schutz A, Schwanke C, et al
    Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
    PLoS One. 2020;15:e0229239.
    PubMed     Abstract available


  75. KHAN HU, Khan S, Shah MA, Attaullah S, et al
    Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naive HCV positive Pakistani patients.
    PLoS One. 2020;15:e0231480.
    PubMed     Abstract available


  76. DOMINGUEZ-RODRIGUEZ S, Prieto L, Fernandez McPhee C, Illan-Ramos M, et al
    Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain.
    PLoS One. 2020;15:e0230109.
    PubMed     Abstract available


  77. PAZGAN-SIMON M, Kukla M, Zuwala-Jagiello J, Derra A, et al
    Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
    PLoS One. 2020;15:e0227459.
    PubMed     Abstract available


  78. WILLIAMS SH, Levy A, Yates RA, Somaweera N, et al
    Discovery of Jogalong virus, a novel hepacivirus identified in a Culex annulirostris (Skuse) mosquito from the Kimberley region of Western Australia.
    PLoS One. 2020;15:e0227114.
    PubMed     Abstract available


  79. PRINSENBERG T, Rebers S, Boyd A, Zuure F, et al
    Dried blood spot self-sampling at home is a feasible technique for hepatitis C RNA detection.
    PLoS One. 2020;15:e0231385.
    PubMed     Abstract available


  80. CHIU SM, Tsai MC, Lin CY, Chen CH, et al
    Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment.
    PLoS One. 2020;15:e0231102.
    PubMed     Abstract available


  81. KRACHT PAM, Arends JE, Hoepelman AIM, Vervoort SCJM, et al
    The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study.
    PLoS One. 2020;15:e0230756.
    PubMed     Abstract available


  82. WEITZEL T, Rodriguez F, Noriega LM, Marcotti A, et al
    Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: A cross-sectional serosurvey.
    PLoS One. 2020;15:e0227776.
    PubMed     Abstract available


  83. WAKE T, Tateishi R, Fukumoto T, Nakagomi R, et al
    Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
    PLoS One. 2020;15:e0231836.
    PubMed     Abstract available


  84. WON YK, Kang KS, Gonzalez YS, Razavi H, et al
    A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    PLoS One. 2020;15:e0232186.
    PubMed     Abstract available


  85. PIECHA F, Ganssler JM, Ozga AK, Wehmeyer MH, et al
    Treatment and re-treatment results of HCV patients in the DAA era.
    PLoS One. 2020;15:e0232773.
    PubMed     Abstract available


  86. AKHTAR S, Nasir JA, Usman M, Sarwar A, et al
    The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0232931.
    PubMed     Abstract available


  87. NGUYEN DT, Tran TTT, Nghiem NM, Le PT, et al
    Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    PLoS One. 2020;15:e0233446.
    PubMed     Abstract available


  88. HE L, Yuan H, Liang J, Hong J, et al
    Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.
    PLoS One. 2020;15:e0233702.
    PubMed     Abstract available


  89. LIN WC, Lin YS, Chang CW, Chang CW, et al
    Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.
    PLoS One. 2020;15:e0233212.
    PubMed     Abstract available


  90. MORISHITA N, Sakamori R, Yamada T, Kai Y, et al
    Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    PLoS One. 2020;15:e0234811.
    PubMed     Abstract available


  91. STEFFEN G, Sperle I, Leendertz SA, Sarma N, et al
    The epidemiology of Hepatitis B, C and D in Germany: A scoping review.
    PLoS One. 2020;15:e0229166.
    PubMed     Abstract available


  92. DURACINSKY M, Thonon F, Bun S, Ben Nasr I, et al
    Good acceptability of HIV, HBV, and HCV screening during immigration medical check-up amongst migrants in France in the STRADA study.
    PLoS One. 2020;15:e0235260.
    PubMed     Abstract available



  93. Retraction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2020;15:e0235375.
    PubMed    


  94. BRAIN D, Mitchell J, O'Beirne J
    Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care.
    PLoS One. 2020;15:e0234577.
    PubMed     Abstract available


  95. LEE MH, Lee GA, Lee SH, Park YH, et al
    A systematic review on the causes of the transmission and control measures of outbreaks in long-term care facilities: Back to basics of infection control.
    PLoS One. 2020;15:e0229911.
    PubMed     Abstract available


  96. TRAEGER MW, Pedrana AE, van Santen DK, Doyle JS, et al
    The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
    PLoS One. 2020;15:e0235445.
    PubMed     Abstract available


  97. ZHANG Y, Gao Z, Wang S, Liu J, et al
    Hepatitis C virus genotype/subtype distribution and evolution among Chinese blood donors: Revealing recent viral expansion.
    PLoS One. 2020;15:e0235612.
    PubMed     Abstract available


  98. COPPOCK D, Chou E, Gracely E, Gross R, et al
    Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics.
    PLoS One. 2020;15:e0235778.
    PubMed     Abstract available


  99. TRONINA O, Gotlib J, Malkowski P, Jaworski M, et al
    Translation and validation study of the Polish version of the Brief Hepatitis C Knowledge Scale.
    PLoS One. 2020;15:e0235764.
    PubMed     Abstract available


  100. LI H, Marks KM, Talal AH, van Seggelen WO, et al
    Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing.
    PLoS One. 2020;15:e0235237.
    PubMed     Abstract available


  101. TRAN HTL, Morikawa K, Anggakusuma, Zibi R, et al
    OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease.
    PLoS One. 2020;15:e0236447.
    PubMed     Abstract available


  102. PEREIRA FM, Almeida MDCC, Santos FLN, Carreiro RP, et al
    Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil.
    PLoS One. 2020;15:e0223087.
    PubMed     Abstract available


  103. SHAWON MA, Yousuf MAK, Raheem E, Ahmed S, et al
    Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh.
    PLoS One. 2020;15:e0232121.
    PubMed     Abstract available


  104. SAITO K, Fukasawa M, Shirasago Y, Suzuki R, et al
    Comparative characterization of flavivirus production in two cell lines: Human hepatoma-derived Huh7.5.1-8 and African green monkey kidney-derived Vero.
    PLoS One. 2020;15:e0232274.
    PubMed     Abstract available


  105. PALAYEW A, Stumo SR, Cooke GS, Hutchinson SJ, et al
    The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    PLoS One. 2020;15:e0235715.
    PubMed     Abstract available


  106. NGWAGA T, Kong L, Lin D, Schoborg C, et al
    Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    PLoS One. 2020;15:e0237162.
    PubMed     Abstract available


  107. TABU K, Mawatari S, Oda K, Kumagai K, et al
    Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    PLoS One. 2020;15:e0237475.
    PubMed     Abstract available


  108. YEN HH, Su PY, Zeng YH, Liu IL, et al
    Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
    PLoS One. 2020;15:e0237582.
    PubMed     Abstract available


  109. BOBARDT M, Hansson MJ, Mayo P, Ure D, et al
    Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.
    PLoS One. 2020;15:e0237236.
    PubMed     Abstract available


  110. JEPKEMEI KB, Ochwoto M, Swidinsky K, Day J, et al
    Characterization of occult hepatitis B in high-risk populations in Kenya.
    PLoS One. 2020;15:e0233727.
    PubMed     Abstract available


  111. RUIZ-EXTREMERA A, Diaz-Alcazar MDM, Munoz-Gamez JA, Cabrera-Lafuente M, et al
    Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission.
    PLoS One. 2020;15:e0233528.
    PubMed     Abstract available


  112. FAGUNDES RN, Ferreira LEVVC, Pace FHL
    Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
    PLoS One. 2020;15:e0237005.
    PubMed     Abstract available


  113. ASHHAB AA, Rodin H, Campos M, Abu-Sulb A, et al
    Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection.
    PLoS One. 2020;15:e0237398.
    PubMed     Abstract available


  114. DUCHESNE L, Hejblum G, Njouom R, Toure Kane C, et al
    Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa.
    PLoS One. 2020;15:e0238035.
    PubMed     Abstract available


  115. WALDENSTROM J, Nystrom K, Nilsson S, Norkrans G, et al
    The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
    PLoS One. 2020;15:e0237840.
    PubMed     Abstract available


  116. CABEZAS C, Trujillo O, Gonzales-Vivanco A, Benites Villafane CM, et al
    Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2020;15:e0234273.
    PubMed     Abstract available


  117. ANDERSON ES, Russell C, Basham K, Montgomery M, et al
    High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department.
    PLoS One. 2020;15:e0233927.
    PubMed     Abstract available


  118. NIELSEN S, Hansen JF, Hay G, Cowan S, et al
    Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers.
    PLoS One. 2020;15:e0238203.
    PubMed     Abstract available


  119. READY E, Habecker P, Abadie R, Khan B, et al
    Competing forces of withdrawal and disease avoidance in the risk networks of people who inject drugs.
    PLoS One. 2020;15:e0235124.
    PubMed     Abstract available


  120. ASEMAHAGN MA
    Epidemiology of hepatitis B and C virus infections among patients who booked for surgical procedures at Felegehiwot referral hospital, Northwest Ethiopia.
    PLoS One. 2020;15:e0234822.
    PubMed     Abstract available


  121. LI J, Abosmaha E, Coffin CS, Labonte P, et al
    Reticulon-3 modulates the incorporation of replication competent hepatitis C virus molecules for release inside infectious exosomes.
    PLoS One. 2020;15:e0239153.
    PubMed     Abstract available


  122. JARGALSAIKHAN G, Eichner M, Boldbaatar D, Bat-Ulzii P, et al
    Sensitivity and specificity of commercially available rapid diagnostic tests for viral hepatitis B and C screening in serum samples.
    PLoS One. 2020;15:e0235036.
    PubMed     Abstract available


  123. GANDJOUR A
    Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
    PLoS One. 2020;15:e0236543.
    PubMed     Abstract available


  124. OYAMA M, Ohnuki Y, Inoue M, Uruha A, et al
    HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis.
    PLoS One. 2020;15:e0237890.
    PubMed     Abstract available


  125. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
    Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
    PLoS One. 2020;15:e0241199.
    PubMed     Abstract available


  126. GALLACH M, Vergara M, Pedro da Costa J, Miquel M, et al
    Correction: Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2020;15:e0241559.
    PubMed     Abstract available


  127. CARDONA-ARIAS JA, Correa JCC, Higuita-Gutierrez LF
    Prevalence of hepatitis B/C viruses and associated factors in key groups attending a health services institution in Colombia, 2019.
    PLoS One. 2020;15:e0238655.
    PubMed     Abstract available


  128. HAGA H, Sato H, Koseki A, Saito T, et al
    A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus.
    PLoS One. 2020;15:e0242028.
    PubMed     Abstract available


  129. JAVANBAKHT M, Archer R, Klausner J
    Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.
    PLoS One. 2020;15:e0241615.
    PubMed     Abstract available


  130. SEMMO N, Mullhaupt B, Ruckstuhl L, Magenta L, et al
    A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naive patients suffering from fatigue and receiving 3D regimen: The HEMATITE study.
    PLoS One. 2020;15:e0241267.
    PubMed     Abstract available


  131. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
    The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
    PLoS One. 2020;15:e0242601.
    PubMed     Abstract available


  132. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
    Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
    PLoS One. 2020;15:e0242101.
    PubMed     Abstract available


  133. JIANG K, Mohammad MK, Dar WA, Kong J, et al
    Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
    PLoS One. 2020;15:e0239624.
    PubMed     Abstract available


  134. PATIL S, Rao A, Pathak P, Kurle S, et al
    Unsterile injection equipment associated with HIV outbreak and an extremely high prevalence of HCV-A case-control investigation from Unnao, India.
    PLoS One. 2020;15:e0243534.
    PubMed     Abstract available


  135. VETTER BN, Ongarello S, Tyshkovskiy A, Alkhazashvili M, et al
    Sensitivity and specificity of rapid hepatitis C antibody assays in freshly collected whole blood, plasma and serum samples: A multicentre prospective study.
    PLoS One. 2020;15:e0243040.
    PubMed     Abstract available


  136. AKIYAMA MJ, Ross J, Rimawi F, Fox A, et al
    Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study.
    PLoS One. 2020;15:e0242623.
    PubMed     Abstract available


  137. SAZZAD HMS, McCredie L, Treloar C, Lloyd AR, et al
    Violence and hepatitis C transmission in prison-A modified social ecological model.
    PLoS One. 2020;15:e0243106.
    PubMed     Abstract available


  138. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
    Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    PLoS One. 2020;15:e0243725.
    PubMed     Abstract available


  139. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
    Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
    PLoS One. 2020;15:e0243473.
    PubMed     Abstract available


  140. BEKKI S, Hashimoto S, Yamasaki K, Komori A, et al
    Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0241002.
    PubMed     Abstract available


  141. PEARCE ME, Yu A, Alvarez M, Bartlett SR, et al
    Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019.
    PLoS One. 2020;15:e0244575.
    PubMed     Abstract available


  142. KHLAIPHUENGSIN A, Chuaypen N, Sodsai P, Reantragoon R, et al
    Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
    PLoS One. 2020;15:e0244112.
    PubMed     Abstract available


  143. MIGITA K, Nakamura M, Aiba Y, Kozuru H, et al
    Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis.
    PLoS One. 2020;15:e0238540.
    PubMed     Abstract available


  144. POURCHER V, Gourmelen J, Bureau I, Bouee S, et al
    Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France.
    PLoS One. 2020;15:e0243529.
    PubMed     Abstract available


  145. LAWAL MA, Adeniyi OF, Akintan PE, Salako AO, et al
    Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.
    PLoS One. 2020;15:e0243656.
    PubMed     Abstract available


    January 2019
  146. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0223287.
    PubMed     Abstract available


  147. LONDONO MC, Riveiro-Barciela M, Ahumada A, Munoz-Gomez R, et al
    Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    PLoS One. 2019;14:e0221567.
    PubMed     Abstract available


  148. GARCIA A, Moore Boffi S, Gayet-Ageron A, Vernaz N, et al
    Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals.
    PLoS One. 2019;14:e0223649.
    PubMed     Abstract available


  149. RAYAN DA'AS S, Azzeh M
    Subgenotyping and genetic variability of hepatitis C virus in Palestine.
    PLoS One. 2019;14:e0222799.
    PubMed     Abstract available


  150. KUO YH, Kee KM, Hsu NT, Wang JH, et al
    Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening.
    PLoS One. 2019;14:e0222196.
    PubMed     Abstract available


  151. BRENNER N, Mentzer AJ, Butt J, Braband KL, et al
    Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
    PLoS One. 2019;14:e0210407.
    PubMed     Abstract available


  152. GARDINI I, Bartoli M, Conforti M, Mennini FS, et al
    Estimation of the number of HCV-positive patients in Italy.
    PLoS One. 2019;14:e0223668.
    PubMed     Abstract available


  153. MOHD SUAN MA, Said SM, Lim PY, Azman AZF, et al
    Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study.
    PLoS One. 2019;14:e0224459.
    PubMed     Abstract available


  154. BLACKARD JT, Kong L, Rouster SD, Karns R, et al
    CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
    PLoS One. 2019;14:e0224523.
    PubMed     Abstract available


  155. ZHENG Z, Lin J, Lu Z, Su J, et al
    Mortality risk in the population of HIV-positive individuals in Southern China: A cohort study.
    PLoS One. 2019;14:e0210856.
    PubMed     Abstract available


  156. MANUEL SOUSA J, Vergara M, Pulido F, Sanchez Antolin G, et al
    Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r +/- dasabuvir +/- ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    PLoS One. 2019;14:e0225061.
    PubMed     Abstract available


  157. ZUCKERMAN AD, Douglas A, Whelchel K, Choi L, et al
    Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
    PLoS One. 2019;14:e0225434.
    PubMed     Abstract available


  158. HAMADEH A, Feng Z, Krahn M, Wong WWL, et al
    A model-based framework for chronic hepatitis C prevalence estimation.
    PLoS One. 2019;14:e0225366.
    PubMed     Abstract available


  159. SHENGE JA, Odaibo GN, Olaleye DO
    Correction: Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0225679.
    PubMed     Abstract available


  160. MUCKE MM, Maasoumy B, Dietz J, Mucke VT, et al
    Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy.
    PLoS One. 2019;14:e0224751.
    PubMed     Abstract available



  161. Retraction: Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    PLoS One. 2019;14:e0225971.
    PubMed    


  162. PAGE K, Evans JL, Hahn JA, Vickerman P, et al
    HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco.
    PLoS One. 2019;14:e0226166.
    PubMed     Abstract available


  163. FILHO HRM, Bierrenbach ALS, Capuani MLD, Mendrone A Jr, et al
    Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study.
    PLoS One. 2019;14:e0226566.
    PubMed     Abstract available


  164. SHIFERAW E, Tadilo W, Melkie I, Shiferaw M, et al
    Sero-prevalence and trends of transfusion-transmissible infections among blood donors at Bahir Dar district blood bank, northwest Ethiopia: A four year retrospective study.
    PLoS One. 2019;14:e0214755.
    PubMed     Abstract available


  165. BOATENG R, Mutocheluh M, Dompreh A, Obiri-Yeboah D, et al
    Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naive individuals in Kumasi, Ghana.
    PLoS One. 2019;14:e0215377.
    PubMed     Abstract available


  166. MORRIS MD, Andrew E, Tan JY, Maher L, et al
    Injecting-related trust, cooperation, intimacy, and power as key factors influencing risk perception among drug injecting partnerships.
    PLoS One. 2019;14:e0217811.
    PubMed     Abstract available


  167. CHENG YW, Chang YC, Chen YL, Chen RC, et al
    Feasibility of measuring spleen stiffness with MR elastography and splenic volume to predict hepatic fibrosis stage.
    PLoS One. 2019;14:e0217876.
    PubMed     Abstract available


  168. ROBERTS H, Boktor SW, Waller K, Daar ZS, et al
    Underreporting of Hepatitis B and C virus infections - Pennsylvania, 2001-2015.
    PLoS One. 2019;14:e0217455.
    PubMed     Abstract available


  169. FREMPONG MT, Ntiamoah P, Annani-Akollor ME, Owiredu WKBA, et al
    Hepatitis B and C infections in HIV-1 and non-HIV infected pregnant women in the Brong-Ahafo Region, Ghana.
    PLoS One. 2019;14:e0219922.
    PubMed     Abstract available


  170. YEN YH, Chen CH, Hung CH, Wang JH, et al
    Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data.
    PLoS One. 2019;14:e0222605.
    PubMed     Abstract available


  171. O'CONNOR SM, Mixson-Hayden T, Ganova-Raeva L, Djibo DA, et al
    Integrated HIV surveillance finds recent adult hepatitis B virus (HBV) transmission and intermediate HBV prevalence among military in uncharacterized Caribbean country.
    PLoS One. 2019;14:e0222835.
    PubMed     Abstract available


  172. KUNISHIMA H, Yoshida E, Caputo J, Mikamo H, et al
    Estimating the national cost burden of in-hospital needlestick injuries among healthcare workers in Japan.
    PLoS One. 2019;14:e0224142.
    PubMed     Abstract available


  173. GALLAY P, Ure D, Bobardt M, Chatterji U, et al
    The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
    PLoS One. 2019;14:e0217433.
    PubMed     Abstract available


  174. WOLDEGIORGIS AE, Erku W, Medhin G, Berhe N, et al
    Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia.
    PLoS One. 2019;14:e0226890.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: